The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab

Cytokine-induced killer cell transplantation: an innovative adoptive therapy

“…The same result was duplicated in a mouse model; CIK cells with bispecific antibodies had significant reduction in tumor burden and improvement in survival (Chan et al, 2006). In another study, both anti-tumor activity and CIK cell proliferation were increased when redirected to breast and ovarian cell tumor targets with bsAb (Kornacker et al, 2006b). …”

Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma

“…To generate CIK cells in traditional protocols, human PBMCs were incubated in a medium containing IFN-γ for 1 day, followed by incubation in a medium supplemented with anti-CD3 antibody, IL-2, and IL-1β for more than 20 days [5,8,9,[27][28][29][30][31][32][33][34]. Anti-CD3 antibody has been shown to trigger T cell proliferation [7].…”